The Food and Drug Administration on Thursday issued an Early Alert about a “potentially high-risk” issue involving B. Braun Medical Inc.’s Caresite Micro Luer Access Device and said the company has updated use instructions for the product.
The agency said B. Braun sent an Urgent Medical Device Correction letter on Nov. 13 recommending that users inspect the Caresite Micro device after disconnecting a male luer connector and replace the device if leakage, backflow, or a valve that appears to remain open is seen. The affected device is identified as the Caresite Micro Luer Access Device, component number S5404000, according to the FDA.
The FDA said B. Braun has received increasing customer complaints that the piston at the female end of the device remains depressed after disconnection. The company confirmed the absence of silicone lubricant at the piston location and indicated a potential link between insufficient silicone application and the piston sticking, the agency said. If the valve stays open, the FDA said blood, IV fluids, or medicines can leak, and air can get into the line.
The FDA listed possible results such as blood loss, delays or breaks in therapy, loss of medication, air embolism, and a risk of contamination by microbes. The agency said harm depends on the patient’s status, the length of the leak, and how much blood, fluid, or drug is lost, with greater risk for neonates, children, critically ill patients, and those on high-risk or life-sustaining treatments. As of Nov. 3, B. Braun has not reported any serious injuries or deaths linked to the issue, the FDA said.
The company’s Nov. 13 letter, cited by the FDA, advises staff to be informed of the issue and to watch closely for leakage or backflow after disconnection. If a piston does not return to position and leakage is observed, the letter recommends taking steps under institutional procedures to stop fluid or blood loss, assess patients for blood loss, therapy interruption, or suspected air embolism, and follow spill protocols as needed. It instructs that any valve suspected of the issue should be replaced using standard aseptic procedures, with full extension set replacement if the valve is bonded, and valve-only replacement if it is standalone.
The correction is to be extended to the hospital or healthcare facility level, and distributors who further distributed the product are asked to forward the notice, according to the FDA. The agency directed users to check the FDA web page for updates while it reviews information about the issue.
The Caresite Micro Luer Access Device is used to provide a sterile needle-free fluid pathway for administration or aspiration of blood, IV therapy, or medications, the FDA said.
The FDA said U.S. customers with adverse reactions, quality problems, or questions should contact B. Braun at Recalls@bbraunusa.com or 844-903-6417. Health care professionals and consumers may report problems to MedWatch, the FDA Safety Information and Adverse Event Reporting Program.
On Nov. 18, the FDA issued a separate Early Alert about a potentially high-risk issue with Outset Medical Tablo hemodialysis power cords, the agency said.